相关实验视频
Updated: Jun 16, 2025

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
新型2-pyrimidinylindole衍生物的设计,合成和结构-活性关系作为口服可用的抗肥胖剂
Li-Yuan Wei1, Yu-Wei Lin1, Jia-Chun Luo1
1School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou, 510006, China.
研究人员优化了一种2 - 胺英英醇衍生物,发现化合物9ga. 这种新药有效地通过减少脂肪积累和改善小鼠的代谢健康来对抗肥胖,提供了一个有前途的抗肥胖策略.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 全球肥胖流行需要新的,安全的抗肥胖剂.
- 之前的研究发现了2-pyrimidinylindole衍生物Wd3d具有潜在的抗肥胖作用.
研究的目的:
- 为了优化2-pyrimidinylindole支架,增强抗肥胖活性和降低细胞毒性.
- 识别具有提高疗效和代谢稳定性的新衍生物.
主要方法:
- 设计,合成和结构-活性关系 (SAR) 研究 36 种新的 2-pyrimidinylindole 衍生物.
- 强效类型的修改,通过用乙基替换乙基.
- 在饮食诱导的肥胖小鼠模型中的体内评估和作用机制研究.
主要成果:
- 化合物9ga显著降低了甘油三 (TG) 积累 (EC50 = 0.07 μM),细胞毒性低 (IC50 ≈ 24 μM).
- 口服9ga有效降低肥胖小鼠的体重增加,脂肪质量,肝脏质量和脂质积累,表现优于Wd3d.
- 9ga改善了心脏损伤标志物,并通过在早期脂肪生成期间抑制PPARγ通路来调节脂质代谢.
结论:
- 优化的2-pyrimidinylindole衍生物,9ga显示出显著的抗肥胖潜力.
- 这项研究证实了2-pyrimidinylindole衍生物在控制饮食引起的肥胖症方面的治疗承诺.
更多相关视频
07:30A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones
Published on: January 21, 2020
13:09Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet
Published on: July 31, 2021
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Oral Hypoglycemic Agents: Sulfonylureas
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides